



Title	Antiphospholipid Antibodies in Patients with Myasthenia Gravis
Author(s)	Kinoshita, Ikuo; Motomura, Masakatsu; Nagasato, Kunihiko; Ichinose, Katsuhiko; Ohishi, Kiyosumi; Takeo, Gou; Satoh, Akira; Nakamura, Tatsufumi; Yoshimura, Toshiro; Tsujihata, Mitsuhiro; Nagataki, Shigenobu
Citation	Acta medica Nagasakiensia. 1994, 39(1-3), p.41-44
Issue Date	1994-10-25
URL	http://hdl.handle.net/10069/15970
Right	

This document is downloaded at: 2018-07-19T00:25:20Z

Antiphospholipid Antibodies in Patients with Myasthenia Gravis

Ikuo KINOSHITA¹, Masakatsu MOTOMURA¹, Kunihiko NAGASATO¹, Katsuhiro ICHINOSE¹, Kiyosumi OHISHI¹, Gou TAKEO¹, Akira SATOH¹, Tatsufumi NAKAMURA¹, Toshiro YOSHIMURA¹, Mitsuhiro TSUJIHATA², and Shigenobu NAGATAKI¹

¹ The First Department of Internal Medicine, Nagasaki University School of Medicine

² The School of Allied Medical Sciences, Nagasaki University, Nagasaki 852, Japan

We measured antiphospholipid antibodies in sera from 94 patients with myasthenia gravis (MG). We found IgG aCL in 14/94 (14.9%), IgM aCL in 6/94 (6.4%) and LA in 4/56 (7.1%) patients with MG. As a whole 21 of 94 (22.3%) patients with MG had some aPL. There was no correlation between the presence of aPL and the severity of MG, the presence of hyperplasia of thymus, titer of the anti-acetylcholine receptor antibodies or anti-single stranded DNA antibodies. Though the percentage of malignant thymoma with aPL were higher than that of malignant thymoma without aPL, we thought that aPL were not the specific antibody in malignant thymoma. In MG, aPL did not play as the aCL syndrome and seemed to be non-specific antibodies.

Keywords: Antiphospholipid antibody, Anticardiolipin antibody, Myasthenia gravis, Lupus anticoagulant, Anti-single stranded DNA antibody

Introduction

Anticardiolipin antibodies (aCA) belong to antibodies directed against anionic phospholipids¹⁾, and have been reported in many clinical systemic syndromes. Most of these syndromes are related to lupus erythematosus¹⁾²⁾, but are not specific for this disease³⁾. They include neurologic diseases which appear as ischemic thrombotic episodes affecting the arterial or venous system⁴⁾⁵⁾. Other non-stroke syndromes such as myelopathy⁶⁾, Guillain-Barre syndrome⁷⁾, migraine⁸⁾, chorea⁹⁾, seizures¹⁰⁾ and autoimmune neurological diseases¹¹⁾, have been also described in association with raised aCL levels.

In myasthenia gravis (MG), an autoimmune response to the acetylcholine receptor (AChR) in postsynaptic membrane, neuromuscular transmission is impaired¹²⁾¹³⁾. Colaco et al. described that aCA were detected in sera of patients

with multiple sclerosis, MG and Lambert-Eaton myasthenic syndrome¹¹⁾. But Rombos et al¹⁴⁾ reported that there was no significant difference of serum aCA level between MG and the controls. Therefore, relationship between aCA and MG is still not well defined.

In this report, measured antiphospholipid antibodies (aPL), aCA and lupus anticoagulant (LA) in sera of patients with MG and investigated the significance of these antibodies in MG.

Materials and methods

Ninety-four MG patients (31 men and 63 women) were studied. They were diagnosed according to the clinical findings, the electromyography (Harvey-Musland test), Tensilon test, the titer of anti-AChR antibodies¹⁵⁾ and deposition of immune complexes at the motor endplates¹⁶⁾. All blood samples were kept at -70°C until examination. Control sera from 140 healthy subjects were available.

Anticardiolipin antibody assay

The levels of IgG and IgM to aCL were determined by the solid phase enzyme-linked immunosorbent assay with some modifications. In brief, cardiolipin (Sigma, USA) was diluted in ethanol and used to coat microtiter plates with 100 μ l (5 μ g/ml). The plates were dried and washed three times with PBST (0.01MPBS, 0.05% Tween) buffer. The antigen-coated plates were blocked with normal rabbit serum in PBS. The plates were incubated with test sera diluted to 1:50 in the same buffer for 90 minutes (100 m μ l /well), and washed in PBST followed by a 90 minutes incubation with 100 μ l of peroxidase conjugated goat anti-human IgG or IgM (DAKO, Japan). After 3 times of washing, color was developed using o-phenylenediamine (WAKO Pure Chem Indust, Japan) and the reaction was stopped by the addition of 2.5 M H₂SO₄. The optical density (O. D) was measured at 490 nm using an ELISA microtiter reader. The O.D values and positive values of IgG and IgM

Reprint request to : Ikuo Kinoshita, The First Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto-machi, Nagasaki 852, Japan
FAX number: 418-649-5910

in healthy individuals were 0.105, 0.173 and 4.1 %, 2.7 % respectively. The ratio of the O.D of patients to the control was cut off index and the positive was defined as greater than 1.0. Comparisons were made with χ^2 analysis.

Lupus anticoagulant activity

The tissue thromboplastin inhibition was performed¹⁷⁾. The ratio of clotting times at 1:100 and 1:1000 dilutions of thromboplastin were determined. A ratio of 1.3 or greater was defined positive.

Autoantibody testing

Anti-AChR antibodies were assayed by an immunoprecipitation method using human junctional AChR as the antigen¹⁸⁾. Antinuclear antibodies were detected by indirect immunofluorescence method. IgG-class antibodies to single-stranded (ss) and double-stranded (ds) DNA were detected by ELISA kit (MBL, Japan). 2 U/ml or greater was defined positive.

Results

Antiphospholipid antibodies in MG

Raised aCL activity was detected in 19/94 (20.2 %) patients with MG (Fig. 1). Positive of only IgG aCL was 12, only IgM was 4 and both of them was 2. LA was

examined in 56 patients with MG. LA was detected in 4/56 (7.1 %). Two cases had aCL too. In this data, aPL was detected in 21/94 (22.3 %).

Features of 21 MG patients with antiphospholipid antibodies

In 21 MG patients with aPL, the clinical features and laboratory data were shown (Table 1, 2, 3). Three patients were ocular type and the others were generalized type. In their complications, rheumatoid arthritis, schizophrenia, nephrosis and malignant alopecia were observed. In the histology of the thymus, 5 patients had hyperplasia and 6 had thymoma (5 were malignant). The number of hyperplasia of thymus and thymoma were not significantly different in the two groups. But the number of malignant thymoma were higher in this group (5/21, 23.8 %) than in the patients without aPL (3/73, 4.1 %) ($P < 0.005$). There were no patients who had the history of coagulopathy, thrombocytopenia and spontaneous abortion.

Titer of the anti-AChR antibodies were 13.8 ± 28.7 nM, and there were no significant difference in comparison to another 73 MG patients. Two patients with LA had the prolongation of active partial thromboplastin time. Only one patient had a false-positive VDRL. Antinuclear antibodies were positive in 5/21 (23.8 %). Though anti-ssDNA antibodies were positive in 12/21 (57.1 %), there was no significant difference in two groups. Anti-ds DNA antibodies in all patients were negative.

Table 1. Clinical data for MG patients with aPL

case	age/sex	severity (Patten)	thymectomy (histology)	anti-AChR Ab (nM)	complication	steroid therapy
1	37/M	I	-	0.8	-	-
2	30/F	I	-	0.5	-	-
3	31/M	I	+(thymic tissue)*	2.2	-	-
4	26/F	II a	+(thymic tissue)	43.0	-	+
5	44/F	II a	+(hyperplasia)	35.6	-	-
6	47/F	II a	+(thymic tissue)	0.8	-	+
7	57/F	II a	-	20.0	-	-
8	40/M	II a	+(hyperplasia)	2.4	-	-
9	60/F	II a	+(thymoma)	11.2	schizophrenia	+
10	42/F	II a	-	26.0	-	-
11	55/F	II a	+(thymic tissue)	21.2	-	+
12	54/M	II a	-	12.7	rheumatoid arthritis	-
13	52/M	II a	+(malignant thymoma)	0.6	-	+
14	30/F	II a	+(hyperplasia)	89.2	nephrosis	+
15	46/F	II a	+(thymic tissue)	69.2	-	-
16	53/F	II a	-	68.0	-	+
17	46/F	II a	+(hyperplasia)	64.6	-	-
18	70/F	II b	+(malignant thymoma)	2.1	-	+
19	59/F	II c	-(malignant thymoma)**	11.7	-	+
20	67/M	II c	+(malignant thymoma)	31.3	-	+
21	45/M	II c	+(malignant thymoma)	72.4	malignant alopecia	+

* residual thymic tissue

** autopsy case

Table 2. Laboratory data for MG patients with aPL

case	BFP	ANA	LA	anti-DNA Ab(U/ml)		PT(%)	APTT(sec)
				ss	ds		
1	-	-	-	0.9	0.4		
2	-	-	+	0.6	0.3	103	36.7
3	-	-	-	0.7	0.3		
4	-	-	+	1.8	0.7	103	36.6
5	-	-	-	10.6	0.9		
6	-	-	-	0.5	0.3	106	25.0
7	-	-	-	25.3	1.8	81	34.4
8	-	40×	+	3.2	0.8		
9	-	-	-	0.7	0.6	119	29.6
10	-	-	-	3.0	0.7	115	30.3
11	-	-	-	1.8	1.0	79	33.8
12	-	-	-	4.3	0.6		
13	-	-	-	0.9	0.2		
14	-	160×	-	10.2	0.2		
15	-	-	-	0.7	0.4		
16	-	-	-	5.1	1.3		
17	-	-	-	70.1	1.5		
18	-	40×	-	14.0	1.7		
19	-	-	-	49.6	0.9		
20	-	-	-	2.2	0.9		
21	-	80×	-	15.9	0.8		

BFP: biological false positive for serological tests for syphilis

ANA: anti-nuclear antibody

LA: lupus anticoagulant

ssDNA: single-stranded DNA

dsDNA: double-stranded DNA

PT: prothrombin time

APTT: active partial thromboplastin time

Table 3. Correlation of clinical features and aPL in MG patients

	aPL(+) (n = 21)	aPL(-) (n = 73)
Type		
ocular	3	18
generalized	18	55
Thymus		
hyperplasia	5	10
thymoma	6	16
(malignant thymoma)*	(5)	(3)
Anti-AChR Ab(nM) [mean±SD]	27.9±28.7	25.2±91.4

* significantly different ($p < 0.005$)

Discussion

ACL are found in various clinical conditions including infections and connective tissue disease²⁾¹⁸⁾. APL are associated with clinical complications such as thrombocytopenia, deep-vein thrombosis and spontaneous abortion in autoimmune disorders¹⁹⁾. These antibodies have been found in the patients with some neurological diseases, because they cross-react with the brain phospholipids cephalin and sphingomyelin²¹⁾²¹⁾.

In the present study, we detected aPL in sera of MG patients; IgG aCL in 14/94 (14.9%), IgM aCL in 6/94 (6.4%) and LA in 4/56 (7.1%). Therefore, 21 MG patients (22.3%) had some aPL, and our data are not in agreement

with those of Colaco et al. according to which, IgM aCL were more specific in MG than IgG aCL¹¹⁾. There is relatively little cross-reactivity of the aCL with anti-DNA antibodies²²⁾. This may be because the glyceride portion of the phospholipid is essential for antibody binding²³⁾²⁴⁾. These findings raise the possibility that membrane bound phospholipids in association with autologous or exogenous membrane antigens might play a role for the development of autoimmunity¹¹⁾. But in our study, anti-ssDNA antibodies were positive in 12/21 (57.1%) MG patients with aCL and in 26/73 (35.6%) MG patients without aCL, and no significant difference in anti-ssDNA antibodies between these two groups. Though in the complication of thymoma these two groups had no significant difference, the percentage of the malignant thymoma was higher in aCL positive group than in negative group. Thymic hyperplasia and thymoma are thought to play a crucial role in the pathogenesis of MG and the antiskeletal muscle antibodies is reported to be specific or closely associated with thymoma²⁵⁾. In the malignant thymoma with aPL, the patients were small number and 4 of them had anti-ssDNA antibodies. Though aPL were secondly detected by the tissue damage, we thought that aPL were not specific antibodies in the malignant thymoma. In MG, aPL were thought not to play as the aPL syndrome and had no correlation with severity of the MG and anti-AChR antibodies. In conclusion, aPL were detected in about 20%

of MG patients but we could not observe the relation between these antibodies and MG. These data suggest that these antibodies had no activity of the aPL syndrome and were non-functional as polyclonal antibodies in MG.

Further studies are needed to confirm the relationship of these antibodies and pathogenesis of MG.

References

- 1 Harris EN, Gharavi AE, Hughes GRV. Antiphospholipid antibodies. *Clin Rheum Dis* 11: 591-593, 1985.
- 2 Harris EN, Gharavi AE, Boey ML, Patel B, Mackworth C, Loizou S. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. *Lancet* 2: 1211-1214, 1983.
- 3 Manoussakis MN, Gharavi AE, Drosos AA, Kitridou RC, Moutsopoulos HM. Anticardiolipin antibodies in unselected autoimmune rheumatic disease patient. *Clin Immunol Immunopathol* 44: 297-307, 1987.
- 4 Briley DP, Coull RM, Goonight Jr SH. Neurological disease associated with antiphospholipid antibodies. *Ann Neurol* 25: 221-227, 1989.
- 5 Levine SR, Deegan MJ, Futrell N, Welch KMA. Cerebrovascular and neurological disease associated with antiphospholipid antibodies: 48 cases. *Neurology* 40: 1181-1189, 1990.
- 6 Harris EN, Gharavi AE, Mackworth Young CG. Lupoid sclerosis: a possible pathogenetic role for antiphospholipid antibodies. *Ann Rheum Dis* 49: 281-283, 1985.
- 7 Frampton G, Winer JB, Cameron JS, Hughes RAC. Severe Guillain-Barre syndrome: an association with IgA anti-cardiolipin antibody in a series of 92 patients. *J Neuroimmunol* 19: 133-139, 1988.
- 8 Brandt KD, Lessells. Migrainous phenomenon in systemic lupus erythematosus. *Arthritis Rheum* 21: 7-19, 1978.
- 9 Lubbe WF, Walker EB. Chorea gravidarum associated with circulating lupus anticoagulant: successful out of pregnancy with prednisone and aspirin therapy. *Br J Obstet Gynaecol* 90: 487-490, 1983.
- 10 Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. *J Rheumatol* 13: 486-489, 1986.
- 11 Colaco CB, Scadding GK, Lockhart S. Anti-cardiolipin antibodies in neurological disorders: cross-reaction with anti-single stranded DNA activity. *Clin Exp Immunol* 68: 313-319, 1987.
- 12 Kinoshita I, Nakamura T, Satoh A, Matsuo H, Seto M, Tomita I, Tsujihata M, Nagataki S. Role of the macrophage in the pathogenesis of experimental autoimmune myasthenia gravis. *J Neurol Sci* 87: 49-59, 1988.
- 13 Patrick J, Lindstrom JM. Autoimmune response to acetylcholine receptor. *Science* 180: 871-872, 1973.
- 14 Rombos A, Evangelopoulou-Katsiri E, Leventakou A, Voumvourakis K, Triantafyllou N, Papageorgiou C. Serum IgG and IgM anticardiolipin antibodies in neurological disease. *Acta Neurol Scand* 81: 243-245, 1990.
- 15 Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic values. *Neurology (Minneapolis)* 26: 1054-1059, 1976.
- 16 Tsujihata M, Yoshimura T, Satoh A, Kinoshita I, Mathuo H, Mori M, Nagataki S. Diagnostic significance of IgG, C3 and C9 at the limb muscle motor end-plate in minimal myasthenia gravis. *Neurology (Minneapolis)* 39: 1359-1363, 1989.
- 17 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. *Blood* 48: 499-504, 1976.
- 18 Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. *Clin Immunol Immunopathol* 41: 8-11, 1986.
- 19 Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. *Br Med J* 287: 1088, 1983.
- 20 Chaleomchan W, Hemachdha T, Sakulramrung R, Deesomchok U. Anticardiolipin antibodies in patients with rabies vaccination induced neurological complications and other neurological diseases. *J Neurol Sci* 96: 143-151, 1990.
- 21 Levine SR, Welch KMA. The spectrum of neurologic disease associated with antiphospholipid antibodies. *Arch Neurol* 44: 876-883, 1987.
- 22 Harris EN, Gharavi AE, Tincani A, Chan JKH, Englert H, Mantell P, Allegro F, Ballestrieri G, Hughes GRV. Affinity purified anticardiolipin and anti-DNA antibodies. *J Clin Lab Immunol* 17: 155-162, 1985.
- 23 Rauch J, Tanerbaum H, Stollar BD, Schwariz RS. Monoclonal anticardiolipin antibodies bind to DNA. *Eur J Immunol* 14: 529-534, 1984.
- 24 Smeenk RJT, Lucasse WAM, Sweak TJG. Is anticardiolipin activity a cross-reaction of anti-DNA or separate activity? *Arthritis Rheum* 30: 607-617, 1987.
- 25 Gilhus NE, Aarli JA, Janzen RWC, Otto HF, Fassel E, Matre R. Skeletal muscle antibodies in patients with a thymic tumor but without myasthenia gravis. *J Neuroimmunol* 8: 69-78, 1985.